DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t4bxld/spiriva_asthma) has announced the addition of the "Spiriva (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
Boehringer Ingelheim's Spiriva (tiotropium bromide) is marketed for the treatment of COPD in all the markets covered by this report. This drug is a long-acting antimuscarinic/anticholinergic agent that causes bronchodilation by inhibiting the M3 muscarinic receptors located in the smooth muscles of the airway. It works by enlarging the airways to allow for easier breathing. Our primary research revealed that physicians use Spiriva off-label for the treatment of moderate to severe persistent asthma.
- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Spiriva including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Spiriva for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Spiriva (tiotropium bromide)
For more information visit http://www.researchandmarkets.com/research/t4bxld/spiriva_asthma